Cross-protection of a new type 2 porcine reproductive and respiratory syndrome virus (PRRSV) modified live vaccine (Fostera PRRS) against heterologous type 1 PRRSV challenge in growing pigs

Park, Changhoon; Choi, Kyuhyung; Jeong, Jiwoon; Chae, Chanhee

doi:10.1016/j.vetmic.2015.02.020

Cited by 36 publications

(37 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After a homologous challenge, the VN antibodies against the challenge virus are boosted [8,15,36,37] in contrast with a genotypically heterologous challenge where no VN antibodies against the challenge virus are detected [38,39]. After challenge with the subtype 3 strain Lena, VN antibodies against Lena were only detected in one UNISTRAIN ® PRRS-vaccinated animal during 2 weeks.…”

Section: Discussionmentioning

confidence: 99%

Modified-live PRRSV subtype 1 vaccine UNISTRAIN® PRRS provides a partial clinical and virological protection upon challenge with East European subtype 3 PRRSV strain Lena

et al. 2016

View full text Add to dashboard Cite

BackgroundWestern European porcine reproductive and respiratory syndrome virus (PRRSV) strains cause limited and mild clinical signs whereas more virulent strains are circulating in Eastern Europe. The emergence of such highly virulent strains in Western Europe might result in severe clinical problems and a financial disaster. In this context, the efficacy of the commercial modified-live PRRSV subtype 1 vaccine UNISTRAIN® PRRS was tested upon challenge with the East European subtype 3 PRRSV strain Lena.ResultsThe mean duration of fever was shortened and the number of fever days was significantly lower in vaccinated pigs than in control pigs. Moreover, a lower number of vaccinated animals showed fever, respiratory disorders and conjunctivitis. The mean virus titers in the nasal secretions post challenge (AUC) were significantly lower in the vaccinated group than in the control group. The duration of viremia was slightly shorter (not significantly different) in the vaccinated group as compared to the control group.ConclusionsVaccination of pigs with the modified-live vaccine UNISTRAIN® PRRS provides a partial clinical and virological protection against the PRRSV subtype 3 strain Lena.

show abstract

Section: Discussionmentioning

confidence: 99%

Modified-live PRRSV subtype 1 vaccine UNISTRAIN® PRRS provides a partial clinical and virological protection upon challenge with East European subtype 3 PRRSV strain Lena

et al. 2016

View full text Add to dashboard Cite

show abstract

“…PRRSV viremic titers are also one of the most important parameters and are strongly correlated with the outcomes of PRRSV infection (Labarque et al 2003). In this challenge model, the virulent TSYM-strain triggered high viremia titers (6.84±0.23 log 10 copies/µL) of PRRSV in the UnV pigs and this level of viral titer was similar to those of highly pathogenic-PRRSV (Guo et al 2013;Park et al 2015). In this study, the mean values of PRRSV viremic titer of the MLV group was consistently lower than that of the UnV group during the period from 4 to 21 DPC.…”

Section: Discussionmentioning

confidence: 65%

“…This MLV vaccine was derived from a US PRRSV isolate (P129) that was sequentially attenuated in a porcine-originated cell line, rather than other species. To the best of our knowledge, it has been proven that Fostera PRRS can elicit immunogenicity and broad cross-protection against lineages 1, 5, 8 and 9 of type II and even type I PRRSV (Calvert et al 2017;Choi et al 2016;Do et al 2015;Park et al 2015;Park et al 2014;Savard et al 2016). However, there is very little information regarding the cross-protection of commercial vaccines against lineage 3 of type II PRRSV so far.…”

Section: Introductionmentioning

confidence: 99%

Peer Review #1 of "Evaluation of a type 2 modified live porcine reproductive and respiratory syndrome vaccine against heterologous challenge of a lineage 3 highly virulent isolate in pigs (v0.1)"

Mickaël¹

2020

View full text Add to dashboard Cite

Porcine reproductive and respiratory syndrome (PRRS) is one of the most common diseases in the global swine industry. PRRSV is characterized by rapid mutation rates and extensive genetic divergences. It is divided into two genotypes, which are composed of several distinct sub-lineages. The purpose of the present study was to evaluate the crossprotective efficacy of Fostera PRRS MLV, an attenuated lineage 8 strain, against the heterologous challenge of a lineage 3 isolate. Eighteen pigs were randomly divided into mock, MLV and unvaccinated (UnV) groups. The pigs in the MLV group were administered Fostera PRRS vaccine at 3 weeks of age and both the MLV and UnV groups were inoculated with a virulent PRRSV isolate at 7 weeks. Clinically, the MLV group showed a shorter duration and a lower magnitude of respiratory distress than the UnV group. The average days of fever in the MLV group was 3.0±0.5, which was significantly lower than the 6.2±0.5 days of the UnV group (P<0.001). The average daily weight gains of the mock, MLV and UnV groups were 781±31, 550±44 and 405±26 g/day, respectively, during the post-challenge phase. The pathological examinations revealed that the severity of interstitial pneumonia in the MLV group was milder compared to the UnV group. Furthermore, PRRSV viremia titers in the MLV pigs were consistently lower (10 1-10 1.5 genomic copies) than those of the UnV pigs from 4 to 14 DPC. In conclusion, vaccination with Fostera PRRS MLV confers partial cross-protection against heterologous challenge of a virulent lineage 3 PRRSV isolate.

show abstract

“…We observed that previously vaccinated animals challenged with a virulent virus developed higher neutralizing titers against this virus than naïve animals that were exposed to the same virulent virus. The rapidity of this neutralizing antibody response should ultimately lead to earlier clearance of the virus and explains at least part of the heterologous protection which has been previously described in prior PRRSV challenge studies (36)(37)(38)(39). The memory B cell is likely the cause of this swift neutralizing antibody response and further investigation following the path laid out by Goldeck et al may be rewarding in discovering potentially conserved neutralizing epitopes (40).…”

Section: Discussionmentioning

confidence: 87%

The PRRSV-Specific Memory B Cell Response Is Long-Lived in Blood and Is Boosted During Live Virus Re-exposure

et al. 2020

View full text Add to dashboard Cite

Porcine reproductive and respiratory syndrome virus (PRRSV) is an important pathogen of swine health and well-being worldwide largely due to an insufficient understanding of the adaptive immune response to infection leading to ineffective PRRSV control. The memory and anamnestic response to infection are critical gaps in knowledge in PRRSV immunity. The lack of effective tools for the evaluation of the memory response previously hindered the ability to effectively characterize the porcine memory response to infection. However, the creation and validation of a PRRSV nsp7-specific B cell tetramer now facilitates the ability to detect very rare memory B cells and thus define the memory response of the pig. Here, we describe the PRRSV nsp7-specific B cell response following vaccination and challenge in six key secondary lymphoid organs including the identification of PBMCs as the tissue of interest for the memory immune response in pigs. Following live virus challenge of immune animals, an anamnestic response of nsp7-specific memory B cells and neutralizing antibodies was observed. This characterization of the functional humoral immune response to PRRSV answers key questions involved in regional specialization of the immune response following intramuscular inoculation of PRRSV MLV.

show abstract

Cross-protection of a new type 2 porcine reproductive and respiratory syndrome virus (PRRSV) modified live vaccine (Fostera PRRS) against heterologous type 1 PRRSV challenge in growing pigs

Cited by 36 publications

References 42 publications

Modified-live PRRSV subtype 1 vaccine UNISTRAIN® PRRS provides a partial clinical and virological protection upon challenge with East European subtype 3 PRRSV strain Lena

Modified-live PRRSV subtype 1 vaccine UNISTRAIN® PRRS provides a partial clinical and virological protection upon challenge with East European subtype 3 PRRSV strain Lena

Peer Review #1 of "Evaluation of a type 2 modified live porcine reproductive and respiratory syndrome vaccine against heterologous challenge of a lineage 3 highly virulent isolate in pigs (v0.1)"

The PRRSV-Specific Memory B Cell Response Is Long-Lived in Blood and Is Boosted During Live Virus Re-exposure

Contact Info

Product

Resources

About